University of Oklahoma

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

175

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

6 drugs in development

Approved1

Phase 31

Phase 21

Phase 13

Preclinical1

By Therapeutic Area

top 6

Oncology

538%

Immunology

18%

Gastroenterology

18%

Musculoskeletal

18%

Infectious Disease

18%

Psychiatry

18%

R&D Momentum

81/100

Pipeline Velocity

57/100

Trial Completion Rate

71/100

Pipeline Concentration

21/100

Pipeline Freshness

69/100

Strategic Signals

↗Active in Immunology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Oct 28, 2026

Recruiting

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy: A First in Human Randomized Pilot Study. Neuromodulation in Cancer Study (OU-SCC-NCAN)

Oct 28, 2026

Recruiting

Application of ctDNA Assay in the Neoadjuvant and Adjuvant Chemotherapy Setting in Patients With Resectable Pancreatic Cancer

Oct 22, 2026

Completed

Self-Acceptance and Supportive Accountability for Active Living Among Adults Receiving Chemotherapy

Earlier

Oct 21, 2026TrialTesting the Feasibility and Acceptability of a Remotely Delivered Program to Promote Active Living Among People With Advanced Cancer

Oct 17, 2026TrialKetamine Oral Rinse in the Management of Oral Mucositis in Head and Neck Cancer Patients Undergoing Radiation Therapy

Oct 17, 2026TrialCare Coordination and Communication Program in Oncology for Tribal Health Systems (C3PO)

Oct 17, 2026TrialA Phase II, Single Arm Study of Atezolizumab + Bevacizumab in Women With Advanced, Recurrent or Persistent Endometrial Cancer

Oct 14, 2026TrialLow Level Transcutaneous Tragus Stimulation to Reduce Inflammation, Dyspnea and Improve Heart Rate Variability in Acute Decompensated Heart Failure

4 more events

Oct 14, 2026TrialCharacterizing the Genomic Landscape of Cancer in Native American Populations (NAT-Geno)

Oct 10, 2026TrialEvaluating the Feasibility and Acceptability of a Single-session Pain Education Class for Patients With Cancer and Pain

Oct 7, 2026TrialAlpha-Ketoglutarate: A Novel Therapeutic Strategy to Improve Neurogliovascular Coupling and Cognitive Aging in Older Adults

Sep 23, 2026TrialInflammation and Biopsy-site-marker in Breast Cancer (MOSAIC)

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Gastroenterology(1 drug)

—

Gastroenterology(1 drug)

Immunology(1 drug)

—

Immunology(1 drug)

Infectious Disease(1 drug)

—

Infectious Disease(1 drug)

Musculoskeletal(1 drug)

—

Musculoskeletal(1 drug)

Neurology(1 drug)

—

Neurology(1 drug)

Oncology(5 drugs)

—

Oncology(5 drugs)

Psychiatry(1 drug)

—

Psychiatry(1 drug)

Unknown / Other(2 drugs)

—

Unknown / Other(2 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)